WZWenqian Zhang

Wenqian Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenqian Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chenxi Zheng

    Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chong Qing, China

    1 shared publication
  • Chuan Qin

    Department of Gastrointestinal Surgery, Chongqing University Three Gorges Hospital, Chongqing 404031, China

    1 shared publication
  • Danzhou Fang

    Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chong Qing, China

    1 shared publication
  • Gengbiao Yuan

    Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Han Zhang

    Department of Oncology, Chongqing University Three Gorges Hospital, Chongqing 404031, China

    1 shared publication
  • Huayi Zhao

    Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chong Qing, China

    1 shared publication

Latest Publications

  • Open Access

    Screening HCC Patients Who Can Benefit from the Sequential Treatment of Conversion Therapy and Radical Surgery and Constructing a Predictive Model

    by Lei Liu, Chuan Qin, Kai Lei, Han Zhang, Wenqian Zhang

    Background/Objective: This study aimed to develop a new nomogram to predict the likelihood of benefit for patients with advanced HCC who can benefit from the sequential treatment of conversion therapy and radical surgery. Materials and Methods: A total of 589 patients who met the criteria were included in this study. According to a 7:3 ratio, the development group included 412 patients, while the validation group included 177 patients. The clinical outcome set for this study was whether one could benefit from radical resection after conversion therapy. Independent risk factors for the outcome were screened through univariable and multivariable Logistic regression analysis. We constructed a nomogram using independent risk factors. The areas under the receiver operating characteristic (ROC) curve, calibration curve, and clinical decision curve were used to evaluate the performance of the model. Results: Sex (OR = 2.000; 95% CI: 1.018, 3.931; p = 0.044), AFP (OR = 0.533; 95% CI: 0.313, 0.907; p = 0.020), targeted therapy and immunotherapy (OR = 3.283; 95% CI: 2.029, 5.312; p < 0.001), and postoperative TACE (OR = 6.544; 95% CI: 4.021, 10.649; p < 0.001) were identified as independent risk factors for determining whether there was a benefit. The AUCs of the nomogram for the development set and the validation set were 0.793(95% CI: 0.749–0.836) and 0.770 (95% CI: 0.697–0.844), respectively. The calibration curves and clinical decision curves of the nomogram indicate that it has good predictive performance. Conclusions: This study developed a nomogram for predicting whether HCC patients can benefit from the sequential treatment of conversion therapy and radical surgery. This is of great help for us to formulate treatment strategies for patients with advanced HCC.

  • Open Access

    Diagnosis of thyroid disease using deep convolutional neural network models applied to thyroid scintigraphy images: a multicenter study

    by Huayi Zhao, Chenxi Zheng, Huihui Zhang, Maohua Rao, Yixuan Li, Danzhou Fang, Jiahui Huang, Wenqian Zhang, Gengbiao Yuan

    Objectives: The aim of this study was to improve the diagnostic performance of nuclear medicine physicians using a deep convolutional neural network (DCNN) model and validate the results with two multicenter datasets for thyroid disease by analyzing clinical single-photon emission computed tomography (SPECT) image data.Methods: In this multicenter retrospective study, 3194 SPECT thyroid images were collected for model training (n=2067), internal validation (n=514) and external validation (n=613). First, four pretrained DCNN models (AlexNet, ShuffleNetV2, MobileNetV3 and ResNet-34) for were tested multiple medical image classification of thyroid disease types (i.e., Graves’ disease, subacute thyroiditis, thyroid tumor and normal thyroid). The best performing model was then subjected to fivefold cross-validation to further assess its performance, and the diagnostic performance of this model was compared with that of junior and senior nuclear medicine physicians. Finally, class-specific attentional regions were visualized with attention heatmaps using gradient-weighted class activation mapping.Results: Each of the four pretrained neural networks attained an overall accuracy of more than 0.85 for the classification of SPECT thyroid images. The improved ResNet-34 model performed best, with an accuracy of 0.944. For the internal validation set, the ResNet-34 model showed higher accuracy (p < 0.001) when compared to that of the senior nuclear medicine physician, with an improvement of nearly 10%. Our model achieved an overall accuracy of 0.931 for the external dataset, a significantly higher accuracy than that of the senior physician (0.931 vs. 0.868, p < 0.001).Conclusion: The DCNN-based model performed well in terms of diagnosing thyroid scintillation images. The DCNN model showed higher sensitivity and greater specificity in identifying Graves’ disease, subacute thyroiditis, and thyroid tumors compared to those of nuclear medicine physicians, illustrating the feasibility of deep learning models to improve the diagnostic efficiency for assisting clinicians.